Merit Financial Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Merit Financial Group’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,750	Closed	-$6.85K	–	747
2022 Q4	$6.85K	Sell	15,750 -2,000	-11%	-$649	﹤0.01%	691
2022 Q3	$5K	Hold	17,750	–	–	﹤0.01%	575
2022 Q2	$6K	Buy	+17,750	New	+$7.35K	﹤0.01%	581

Other funds holding SIOX

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Merit Financial Group's SIOX Position: Q1 2023 in Review

Merit Financial Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 15,750 shares — an estimated $6.85K sold.

Merit Financial Group first reported a position in SIOX in Q2 2022 and held it in 3 quarters. The position peaked at $6.85K in Q4 2022. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

Merit Financial Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Merit Financial Group sold 15,750 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $6.85K.
Merit Financial Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Merit Financial Group's Sio Gene Therapies Inc. Common Stock position peaked at $6.85K in Q4 2022.
4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Merit Financial Group's 13F filing for Q1 2023, filed 24 Apr 2023.